Ohio State Earns NCI Phase II Contract Renewal

The National Cancer Institute (NCI) has awarded the OSUCCC – James a phase II clinical trials contract that could be worth more than $8 million over five years if fulfilled to capacity. Principal investigator Miguel Villalona, MD, says the money, a renewal of a similar $3 million NCI contract awarded to Ohio State in 2006, will enable the OSUCCC – James to conduct phase II clinical trials on NCI-sponsored agents as the lead institution in a four-member consortium that is one of only seven consortia holding NCI phase II contracts.